Ann: CE, FDA and CFDA Approval - Guangzhou Production Facility, page-290

(ii) Class B Performance Rights: the Company receives cumulative revenue of US$30,000,000 during any continuous period of 12 months within 24 months from Admission; and
(iii) Class C Performance Rights: the Company cumulative EBITDA during the period of 36 months following the date of Admission is US$25,000,000.

Class B is a stretch considering only a little over 5 months to go and still needing ~ 29m. That’s an average of 6m a month in sales.

If Yacov can hits Class C he deserves every single share. I’m pretty sure no one will object either. The share price will definitely be $.